Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - lansoprazole, quantity: 30 mg - tablet, orally disintegrating - excipient ingredients: crospovidone; magnesium carbonate hydrate; aspartame; macrogol 6000; sodium bicarbonate; iron oxide yellow; sodium starch glycollate type a; citric acid monohydrate; hyprolose; magnesium stearate; mannitol; sodium lauryl sulfate; purified talc; iron oxide red; microcrystalline cellulose; sodium hydroxide; triethyl citrate; polysorbate 80; methacrylic acid - ethyl acrylate copolymer (1:1); sucrose; maize starch; flavour - adults,1.healing and long-term management of reflux oesophagitis. ,2.healing and long-term management for patients with duodenal ulcer. ,3.healing of benign gastric ulcer. patients whose gastric or duodenal ulcer is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. ,4.lansoprazole is also effective in patients with benign peptic lesions that do not respond to h2-receptor antagonists. ,5.eradication of h. pylori from the upper gastrointestinal tract in patients with peptic ulcer or chronic gastritis when used in combination with appropriate antibiotics (see clinical trials). ,6.relief of reflux-like and/or ulcer-like symptoms associated with acid-related dyspepsia. ,paediatric patients 6 to 17 years of age. ,1.treatment of gastro-oesophageal reflux disease, including all grades of oesophagitis. ,2.healing of erosive oesophagitis.

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

apotex inc. - lansoprazole - capsules delayed-release - 30mg

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - lansoprazole - capsules - lansoprazole 15 mg - lansoprazole - lansoprazole - for the treatment of duodenal ulcer, benign gastric ulcer, reflux oesophagitis and acid related disorders of the upper gastrointestinal tract. healing, long term treatment and maintenance therapy for patients with gastro oesophageal reflux disease (gord) or duodenal ulcer. prevention of relapse in patients with gord or duodenal ulcer. eradication of h. pylori from the upper gastrointestinal tract in patients with duodenal ulcer, gastritis or benign ulcer (in combination with appropriate antibiotics). short term treatment (up to four weeks) of heartburn and/or upper epigastric pain associated with acid-related dyspepsia. long-term management of pathological hypersecretory conditions including zollinger ellison syndrome.treatment and prophylaxis of nsaid- associated benign gastric ulcers, duodenal ulcers and relief of symptoms in patients requiring continued nsaid treatment.

Israel - English - Ministry of Health

teva israel ltd - lansoprazole - capsules - lansoprazole 30 mg - lansoprazole - lansoprazole - • treatment of duodenal and gastric ulcer • treatment of reflux oesophagitis• prophylaxis of reflux oesophagitis• eradication of helicobacter pylori (h. pylori) concurrently given with appropriate antibiotic therapy for treatment of h.pylori-associated ulcers• treatment of nsaid-associated benign gastric and duodenal ulcers in patients requiring continued nsaid treatment• prophylaxis of nsaid-associated gastric ulcers and duodenal ulcers in patients at risk requiring continued therapy• symptomatic gastroesophageal reflux disease• zollinger-ellison syndrome.

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - lansoprazole - capsules - lansoprazole 30 mg - lansoprazole - lansoprazole - for the treatment of duodenal ulcer, benign gastric ulcer, reflux oesophagitis and acid related disorders of the upper gastrointestinal tract. healing, long term treatment and maintenance therapy for patients with gastro oesophageal reflux disease (gord) or duodenal ulcer. prevention of relapse in patients with gord or duodenal ulcer. eradication of h. pylori from the upper gastrointestinal tract in patients with duodenal ulcer, gastritis or benign ulcer (in combination with appropriate antibiotics). short term treatment (up to four weeks) of heartburn and/or upper epigastric pain associated with acid-related dyspepsia. long-term management of pathological hypersecretory conditions including zollinger ellison syndrome. treatment and prophylaxis of nsaid- associated benign gastric ulcers, duodenal ulcers and relief of symptoms in patients requiring continued nsaid treatment.

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - lansoprazole (unii: 0k5c5t2qpg) (lansoprazole - unii:0k5c5t2qpg) - lansoprazole delayed-release capsules are indicated in adults for short-term treatment (for four weeks ) for healing and symptom relief of active duodenal ulcer [see clinical studies ( 14.1]. triple therapy: lansoprazole /amoxicillin /clarithromycin lansoprazole delayed-release capsules in combination with amoxicillin plus clarithromycin as triple therapy is indicated in adults for the treatment of patients with h. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) to eradicate h. pylori. eradication of h. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see clinical studies ( 14.2)]. please refer to the full prescribing information for amoxicillin and clarithromycin. dual therapy: lansoprazole /amoxicillin lansoprazole delayed-release capsules in combination with amoxicillin as dual therapy is indicated in adults for the treatment of

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - lansoprazole (unii: 0k5c5t2qpg) (lansoprazole - unii:0k5c5t2qpg) - lansoprazole delayed-release capsules are indicated in adults for short-term treatment (for four weeks ) for healing and symptom relief of active duodenal ulcer [see clinical studies ( 14.1]. triple therapy: lansoprazole /amoxicillin /clarithromycin lansoprazole delayed-release capsules in combination with amoxicillin plus clarithromycin as triple therapy is indicated in adults for the treatment of patients with h. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) to eradicate h. pylori. eradication of h. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see clinical studies ( 14.2)]. please refer to the full prescribing information for amoxicillin and clarithromycin. dual therapy: lansoprazole /amoxicillin lansoprazole delayed-release capsules in combination with amoxicillin as dual therapy is indicated in adults for the treatment of

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - lansoprazole (unii: 0k5c5t2qpg) (lansoprazole - unii:0k5c5t2qpg) - lansoprazole delayed-release capsules are indicated in adults for short-term treatment (for four weeks ) for healing and symptom relief of active duodenal ulcer [see clinical studies ( 14.1]. triple therapy: lansoprazole /amoxicillin /clarithromycin lansoprazole delayed-release capsules in combination with amoxicillin plus clarithromycin as triple therapy is indicated in adults for the treatment of patients with h. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) to eradicate h. pylori. eradication of h. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see clinical studies ( 14.2)]. please refer to the full prescribing information for amoxicillin and clarithromycin. dual therapy: lansoprazole /amoxicillin lansoprazole delaye

United States - English - NLM (National Library of Medicine)

wockhardt limited - lansoprazole (unii: 0k5c5t2qpg) (lansoprazole - unii:0k5c5t2qpg) - lansoprazole 15 mg - lansoprazole delayed-release capsules are indicated for short-term treatment (for 4 weeks) for healing and symptom relief of active duodenal ulcer [see clinical studies (14)]. triple therapy: lansoprazole/amoxicillin/clarithromycin lansoprazole delayed-release capsules in combination with amoxicillin plus clarithromycin as triple therapy is indicated for the treatment of patients with h. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) to eradicate h. pylori. eradication of h. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see clinical studies (14)]. please refer to the full prescribing information for amoxicillin and clarithromycin. dual therapy: lansoprazole/amoxicillin lansoprazole delayed-release capsules in combination with amoxicillin as dual therapy is indicated for the treatment of patients with h. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) who are either allergic or intolerant to

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - lansoprazole, quantity: 30 mg - capsule - excipient ingredients: methacrylic acid - ethyl acrylate copolymer (1:1); hypromellose; indigo carmine; colloidal anhydrous silica; titanium dioxide; maize starch; purified talc; macrogol 300; sucrose; carmoisine; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - adults:. lanzopran capsules are indicated for. - healing and long-term management of reflux oesophagitis. . - healing and long-term management for patients with duodenal ulcer.. - healing of benign gastric ulcer. patients whose gastric or duodenal ulcer is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. . - patients with benign peptic lesions that do not respond to h2-receptor antagonists.. - eradication of h. pylori from the upper gastrointestinal tract in patients with peptic ulcer or chronic gastritis when used in combination with appropriate antibiotics. . - relief of reflux-like and/or ulcer-like symptoms associated with acid-related dyspepsia. . paediatric and adolescent patients i to 17 years of age:. lanzopran capsules are indicated for. - treatment of gastro-oesophageal reflux disease, including all grades of oesophagitis. . - healing of erosive oesophagitis.